Biodexa Successful Outcome of Type C Meeting with FDA Regarding Phase 3

 Clears the way to finalize Phase 3 protocol and recruit sites for U.S.

Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match

regarding the protocol for the planned registrational Phase 3 study of eRapa in familial adenomatous polyposis (“FAP”).

https://www.globenewswire.com/news-release/2025/03/10/3039710/0/en/Biodexa-Announces-Successful-Outcome-of-a-Type-C-Meeting-with-FDA-Regarding-the-Phase-3-Program-for-eRapa-in-FAP.html